Literature DB >> 18765155

Adjuvant therapy for renal cell carcinoma.

Naomi B Haas1, Robert Uzzo.   

Abstract

Currently, the management of localized renal cell carcinoma (RCC) is surgical. Unfortunately, many cases of high-risk RCC recur following resection and develop metastatic disease, an event that usually results in death. Because previous attempts to improve survival with adjuvant therapy have been unsuccessful, the US Food and Drug Administration's approval of three new agents for metastatic RCC has generated renewed interest in evaluating agents in the adjuvant setting for high-risk RCC. This article discusses the rationale for the use of these and other novel agents and reviews currently ongoing adjuvant trials as well as considerations for the development of new trials for adjuvant therapies.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18765155     DOI： 10.1007/s11912-008-0037-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  60 in total

1.  Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study.

Authors:  G Pizzocaro; L Piva; G Di Fronzo; A Giongo; A Cozzoli; E Dormia; S Minervini; A Zanollo; U Fontanella; G Longo
Journal:  J Urol       Date:  1987-12       Impact factor: 7.450

Review 2.  Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options.

Authors:  John S Lam; John T Leppert; Arie S Belldegrun; Robert A Figlin
Journal:  BJU Int       Date:  2005-09       Impact factor: 5.588

3.  p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.

Authors:  Oleg Shvarts; David Seligson; John Lam; Tao Shi; Steve Horvath; Robert Figlin; Arie Belldegrun; Allan J Pantuck
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

4.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

Review 5.  The Heidelberg classification of renal cell tumours.

Authors:  G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar
Journal:  J Pathol       Date:  1997-10       Impact factor: 7.996

6.  Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.

Authors:  Bradley C Leibovich; Ken-ryu Han; Matthew H T Bui; Allan J Pantuck; Frederick J Dorey; Robert A Figlin; Arie Belldegrun
Journal:  Cancer       Date:  2003-12-15       Impact factor: 6.860

7.  Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

Authors:  Joseph I Clark; Michael B Atkins; Walter J Urba; Steven Creech; Robert A Figlin; Janice P Dutcher; Larry Flaherty; Jeffrey A Sosman; Theodore F Logan; Richard White; Geoffrey R Weiss; Bruce G Redman; Christopher P G Tretter; David McDermott; John W Smith; Michael S Gordon; Kim A Margolin
Journal:  J Clin Oncol       Date:  2003-06-16       Impact factor: 44.544

Review 8.  Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.

Authors:  Allan J Pantuck; Gang Zeng; Arie S Belldegrun; Robert A Figlin
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

9.  A mammalian protein targeted by G1-arresting rapamycin-receptor complex.

Authors:  E J Brown; M W Albers; T B Shin; K Ichikawa; C T Keith; W S Lane; S L Schreiber
Journal:  Nature       Date:  1994-06-30       Impact factor: 49.962

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  2 in total

1.  Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.

Authors:  Nicholas J Hellenthal; Willie Underwood; Remedios Penetrante; Alan Litwin; Shaozeng Zhang; Gregory E Wilding; Bin T Teh; Hyung L Kim
Journal:  J Urol       Date:  2010-09       Impact factor: 7.450

Review 2.  Molecular diagnosis and therapy of kidney cancer.

Authors:  W Marston Linehan; Gennady Bratslavsky; Peter A Pinto; Laura S Schmidt; Len Neckers; Donald P Bottaro; Ramaprasad Srinivasan
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.